Review article · 2022

Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy

Ahmed O. Elzoghby, Cristina R. Ferrone, Soldano Ferrone, Mahmoud Lotfi Nasr

Drug Discovery Today, 28(1), 103434 · Published 8 November 2022 · DOI 10.1016/j.drudis.2022.103434

View at the publisherCite this paper

In brief

“Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy” is a 2022 review article by Ahmed O. Elzoghby and 3 co-authors, published in Drug Discovery Today. OpenAlex counts 11 citations as of 21 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
11
Most cited in
2024 (6)
Field-weighted impact
0.27
References
57
Authors
4

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Elzoghby, A. O., Ferrone, C. R., Ferrone, S., & Nasr, M. L. (2022). Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. Drug Discovery Today, 28(1), 103434. https://doi.org/10.1016/j.drudis.2022.103434

MLA 9

Elzoghby, Ahmed O., et al. “Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy.” Drug Discovery Today, vol. 28, no. 1, 2022, p. 103434. https://doi.org/10.1016/j.drudis.2022.103434.

Chicago

Elzoghby, Ahmed O., Cristina R. Ferrone, Soldano Ferrone, and Mahmoud Lotfi Nasr. 2022. “Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy.” Drug Discovery Today 28 (1): 103434. https://doi.org/10.1016/j.drudis.2022.103434.

Harvard

Elzoghby, A. O. et al. (2022) ‘Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy’, Drug Discovery Today, 28(1), p. 103434. doi:10.1016/j.drudis.2022.103434.

IEEE

A. O. Elzoghby, C. R. Ferrone, S. Ferrone, and M. L. Nasr, “Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy,” Drug Discovery Today, vol. 28, no. 1, p. 103434, 2022, doi: 10.1016/j.drudis.2022.103434.

BibTeX

@article{elzoghby2022engineered,
  title     = {{Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy}},
  author    = {Elzoghby, Ahmed O. and Ferrone, Cristina R. and Ferrone, Soldano and Nasr, Mahmoud Lotfi},
  journal   = {Drug Discovery Today},
  year      = {2022},
  volume    = {28},
  number    = {1},
  pages     = {103434},
  doi       = {10.1016/j.drudis.2022.103434},
  url       = {https://doi.org/10.1016/j.drudis.2022.103434}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202322
202466
202511
202622

Its field-weighted citation impact is 0.27: it has been cited 0.27 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research

  • pancreatic cancer
  • nanomedicine
  • immunotherapy resistance
  • immune checkpoint inhibitors
  • cancer-associated fibroblasts
  • dendritic cells
  • tumor microenvironment
  • cytotoxic T lymphocytes

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Elzoghby, A. O., Ferrone, C. R., Ferrone, S., & Nasr, M. L. (2022). Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. Drug Discovery Today, 28(1), 103434. https://doi.org/10.1016/j.drudis.2022.103434

How many times has this paper been cited?

11 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Ahmed O. Elzoghby, Cristina R. Ferrone, Soldano Ferrone, Mahmoud Lotfi Nasr.

What is the DOI of this paper?

10.1016/j.drudis.2022.103434, permanently at https://doi.org/10.1016/j.drudis.2022.103434. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.